Invenomic Fund

Super Institutional Class (BIVSX)

Annual Shareholder Report - October 31, 2024

Fund Overview

This annual shareholder report contains important information about Invenomic Fund for the period of November 1, 2023 to October 31, 2024. You can find additional information about the Fund at **www.invenomic.com**. You can also request this information by contacting us at 1-855-466-3406.

What were the Fund's costs for the last year?

(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Super Institutional Class	\$276	2.91%


How did the Fund perform during the reporting period?

The long portfolio contributed 28.77% while the short portfolio detracted approximately -40.54%, both on a gross basis. During this period, we averaged 109.93% long and -92.39% short resulting in average net exposure of 17.54% and average gross exposure 202.32%.

From a sector perspective, our biggest contributors on the long side were Information Industrials (+6.30%), Financials (+6.17%) and Consumer Discretionary (+5.10%). On the short side, the sectors that detracted the most were Information Technology (-13.22%), Consumer Discretionary (-8.20%) and Financials (-8.09%). From a total portfolio perspective, the top ten contributed 9.79% and the top ten detractors cost -10.62%, both on a gross basis.

Our strategy faced two substantial market headwinds during the year which negatively impacted performance. The first is underperformance of value relative to growth. The Russell 1000 Value/Growth Index was down -10.57% during the period, which is the fifth worst year in the last 25 years. The second and most substantial headwind was the momentum factor which as of October 31, 2024, had its second strongest year in the last 25 years as measured by the Bloomberg US Pure Momentum Factor Index. Considering the strength of the headwinds we faced, we believe we managed risk as well as can be expected. We feel like our portfolio is well positioned for what is likely to be a volatile period going forward.

We expect the market environment to remain volatile for the foreseeable future. The outcome of the U.S. election will create opportunities on the long and the short side regardless of who is elected. Equity valuations remain at extremely elevated levels, and as a result, we will continue to proceed cautiously relying on our investment process, which has served us well over time.





Average Annual Total Returns				
	1 Year	5 Years	Since Inception (May 10, 2019)	
Invenomic Fund	-10.20%	23.83%	21.66%	
S&P Composite 1500 [®] Index	37.54%	14.90%	14.72%	

The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.

Fund Statistics			
Net Assets	\$984,405,991		
Number of Portfolio Holdings	324		
Advisory Fee	\$22,612,478		
Portfolio Turnover	170%		

What did the Fund invest in?







Material Fund Changes

No material changes occurred during the year ended October 31, 2024.

Invenomic Fund - Super Institutional Class (BIVSX)

Annual Shareholder Report - October 31, 2024

Where can I find additional information about the Fund?

Additional information is available on the Fund's website (www.invenomic.com), including its:

- Prospectus
- Financial information
- Holdings
- Proxy voting information